Le Lézard
Classified in: Health
Subject: RCL

Public Advisory - Equate (lemon flavour), Personnelle (lemon flavour) and Life Brand (lemon and cherry flavours) Magnesium citrate oral solution saline laxatives recalled due to potential microbial contamination


OTTAWA, ON, July 24, 2022 /CNW/ -

Summary
Product Image(s):

Equate Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour

Equate Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour (CNW Group/Health Canada)

Life Brand Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour

Life Brand Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour (CNW Group/Health Canada)

Life Brand Magnesium citrate oral solution saline laxative, 300 mL, cherry flavour

Life Brand Magnesium citrate oral solution saline laxative, 300 mL, cherry flavour (CNW Group/Health Canada)

Personnelle Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour

Personnelle Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour (CNW Group/Health Canada)

Affected products

Product

NPN

Lot

Equate Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour

80015316

All lots

Life Brand Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour

80015316

All lots

Life Brand Magnesium citrate oral solution saline laxative, 300 mL, cherry flavour

80015316

All lots

Personnelle Magnesium citrate oral solution saline laxative, 300 mL, lemon flavour

80015316

All lots

Issue

Health Canada is advising that all lots of Equate (lemon flavour), Life Brand (lemon and cherry flavours) and Personnelle (lemon flavour) Magnesium citrate oral solution saline laxative (NPN 80015316) are being recalled by the importer, Shandex Sales Group Ltd. (Shandex Group), due to the possibility of microbial contamination. The company is recalling the products as a precaution in light of a recall in the United States (U.S.) of similar products that are manufactured at the same site.

Magnesium citrate oral solution is used as a laxative for relief of occasional constipation. The product is indicated for use in adults and children two years of age and older.

Microbial testing of the products recalled in the U.S. identified the presence of Gluconacetobacter liquefaciens. Ingesting contaminated product may result in symptoms including abdominal discomfort or pain, diarrhea, nausea and vomiting. Children, pregnant women, the elderly and people with a weakened immune system may be more susceptible to serious adverse effects from microbial contamination.

The Department is monitoring the company's recall and will inform Canadians if any new health risks are identified.

What you should do

Alert / recall type: Public Advisory
Category: Health products ? Natural health products
Published by: Health Canada

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 06:25
Genexine (KOSDAQ: 095700), a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of serious unmet medical needs, announced a merger with EPD Biotherapeutics...

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...



News published on and distributed by: